Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04779879 · ClinicalTrials.gov registry record · Phase 2

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

A Phase 2 study of Covid19, sponsored by Vir Biotechnology.

Completed
Registry status
Phase 2
Development phase
354
Enrollment target
20
Study locations

NCT04779879 is a Phase 2 study of Covid19 that has completed, run by Vir Biotechnology. The registered enrollment target is 354 participants, below the 2,699-participant average among 94 other Covid19 trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04779879, a Phase 2 study of Covid19, has completed, sponsored by Vir Biotechnology.

COMPLETED
Registry status
Phase 2
Development phase
354 participants
Enrollment target
20
Study locations

Study Summary

This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2 (Gen2) and will be assessed for safety, tolerability, and pharmacokinetics.

Conditions Studied

Covid19

Interventions

  • BIOLOGICAL Sotrovimab (Gen1)
  • BIOLOGICAL Sotrovimab (Gen2)

Study Locations (20)

Florida

  • Investigative Site - Ft. Pierce
  • Investigative Site - Gainesville
  • Investigative Site - Hialeah
  • Investigative Site - Miami
  • Investigative Site - Miami
  • Investigative Site - Miami
  • Investigative Site - Miami
  • Investigative Site - Orlando
  • Investigative Site - Pembroke Pines
  • Investigative Site - Tampa

California

  • Investigative Site - Bakersfield
  • Investigative Site - Northridge

Ontario

  • Investigative Site - Sarnia
  • Investigative Site - Toronto

Alabama

  • Investigative Site - Anniston

Georgia

  • Investigative Site - Columbus

Illinois

  • Investigative Site - Winfield

Maryland

  • Investigative Site - Rockville

New York

  • Investigative Site - The Bronx

Trial Details

FieldValue
Enrollment Target 354 participants
Start Date 2021-02-18
Est. Completion 2022-04-06
Phase Phase 2

Sponsor

Vir Biotechnology

13 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04779879

The ClinicalTrials.gov registry entry for NCT04779879 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 354 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,699-participant average among 94 other Covid19 trials with a reported enrollment target (87% lower). The listed sponsor is Vir Biotechnology, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Sotrovimab (Gen1) is the first listed.

NCT04779879 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Ontario.

Frequently Asked Questions

What is clinical trial NCT04779879 about?

NCT04779879 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19". This is a phase 2 study in which subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Sotrovimab) Generation 1 (Gen1) or VIR-7831 (Sotrovimab) Generation 2 (Gen2) and will be assessed for safety, tolerability, and pharmacokinetics.

What is the current status of trial NCT04779879?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 354 participants. The study started on 2021-02-18. Estimated completion is 2022-04-06.

What conditions does trial NCT04779879 study?

This clinical trial studies the following conditions: Covid19.

What interventions are being tested in trial NCT04779879?

The interventions under investigation include: Sotrovimab (Gen1) (BIOLOGICAL), Sotrovimab (Gen2) (BIOLOGICAL).

Who is sponsoring clinical trial NCT04779879?

This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04779879 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Covid19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Covid19

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.